Faldaprevir

Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection[1][2].

Product Specifications

CAS Number

[801283-95-4]

Product Name Alternative

BI 201335

UNSPSC

12352005

Hazard Statement

H302

Target

HCV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/faldaprevir.html

Purity

98.58

Solubility

DMSO : 2 mg/mL (ultrasonic; warming)

Smiles

O=C([C@H](C[C@H]1OC2=CC(C3=CSC(NC(C(C)C)=O)=N3)=NC4=C2C=CC(OC)=C4Br)N(C1)C([C@H](C(C)(C)C)NC(OC5CCCC5)=O)=O)N[C@@]([C@@H]6C=C)(C6)C(O)=O

Molecular Formula

C40H49BrN6O9S

Molecular Weight

869.82

Precautions

H302

References & Citations

[1]Llinàs-Brunet M, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335) . J Med Chem. 2010 Sep 9;53 (17) :6466-76.|[2]Zeuzem S, et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther. 2013;18 (8) :1015-9.